To include your compound in the COVID-19 Resource Center, submit it here.

Living up to expectations

Toolkit companies that went public this year enjoy a robust premium on their valuations compared to more mature toolkit plays as well as profitable product companies. Indeed, comparing market cap to projected 2001 revenues, a sampling of 15 of the toolkit companies that went public this year is trading at nearly triple the multiple of six profitable biotech product companies. Thus, the question is how fast - or whether - these fledgling toolkit developers can ramp up their revenues to justify their valuations.

"Toolkits have had a lot of momentum investors and thus have been afforded a lot of leeway this year," said fund manager Dennis Purcell of Perseus-Soros.

Robertson Stephens analyst Michael King noted that new-to-market companies often enjoy a valuation premium. "There's typically a dichotomy between new and more established companies," he said. "But investors have to realize that maturity takes time. Even Affymetrix wasn't fully mature when it went public."

Thus, as the new become established, Purcell said that "people will be watching whether the new tool companies make their revenue numbers." Because pharma companies are primary purchasers of enabling technologies, he noted that toolkit revenues will be closely tied to what pharma companies are willing to pay. "Whether or not pharma has the capacity to do such a high number of deals will signal whether these new companies are sustainable," Purcell said.

Ultimately, companies may turn to consolidation in order to increase their menu of technology offerings, thereby increasing the dollar value per customer and reducing

Read the full 2475 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE